Clinical Trial Update: 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing drug candidate 601 to ranibizumab in patients with branch retinal vein occlusion has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Branch Retinal Vein Occlusion

Drugs mentioned

• 601
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Conditions: Branch Retinal Vein Occlusion | Phase 2 | Status: COMPLETED